The mortality effects of disregarding the strategy to save doses of measles vaccine: a cluster-randomised trial in Guinea-Bissau.
child health
epidemiology
immunisation
public health
vaccines
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
01
11
2020
revised:
31
03
2021
accepted:
16
04
2021
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
Measles vaccine (MV) may improve health beyond measles protection. To avoid wastage from multi-dose vials, children in Guinea-Bissau are only measles vaccinated when aged 9-11 months and when six or more children are present. We assessed health impacts of providing MV to all measles-unvaccinated children 9-35 months. We cluster-randomised 182 village clusters under demographic surveillance in rural Guinea-Bissau to an 'MV-for-all-policy' arm where we offered MV regardless of age and number of children present at our bi-annual village visits, or a 'Restrictive-MV-policy' arm where we followed national policy. Measles-unvaccinated children aged 9-35 months were eligible for enrolment and followed to 5 years of age. In intention-to-treat analyses, we compared mortality using Cox regression analyses with age as underlying timescale. The primary analysis was for children aged 12-35 months at eligibility assessment. Interactions with several background factors were explored. Between 2011 and 2016, we followed 2778 children in the primary analysis. MV coverage by 3 years was 97% among children eligible for enrolment under the MV-for-all-policy, and 48% under the Restrictive-MV-policy. Mortality was 59% lower than anticipated and did not differ by trial arm (MV-for-all-policy: 45/1405: Restrictive-MV-policy: 44/1373; HR: 0.95 (95% CI 0.64 to 1.43)). The effect of MV-for-all changed over time: The HR was 0.53 (95% CI 0.27 to 1.07) during the first 1½ years of enrolment but 1.47 (95% CI 0.87 to 2.50) later (p=0.02, test of interaction). Explorative analyses indicated that the temporal change may be related to interactions with other childhood interventions. The MV-for-all-policy increased MV coverage but had no overall effect on overall mortality. NCT01306006.
Identifiants
pubmed: 33941513
pii: bmjgh-2020-004328
doi: 10.1136/bmjgh-2020-004328
pmc: PMC8098964
pii:
doi:
Substances chimiques
Measles Vaccine
0
Banques de données
ClinicalTrials.gov
['NCT01306006']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Infect Dis. 2021 May 18;72(10):e596-e603
pubmed: 32949460
J Infect Dis. 2014 Jun 1;209(11):1731-8
pubmed: 24436454
Pediatr Infect Dis J. 2010 Apr;29(4):324-8
pubmed: 19934785
BMJ Open. 2019 Jun 11;9(6):e028775
pubmed: 31189684
Pediatr Infect Dis J. 2006 Aug;25(8):721-7
pubmed: 16874172
BMJ. 2010 Nov 30;341:c6495
pubmed: 21118875
Lancet. 2003 Nov 22;362(9397):1765
pubmed: 14643138
Clin Infect Dis. 2018 May 2;66(10):1573-1580
pubmed: 29177407
BMJ Open. 2016 Dec 23;6(12):e013335
pubmed: 28011813
Pediatr Infect Dis J. 2003 Sep;22(9):798-805
pubmed: 14506371
Pediatr Infect Dis J. 2015 Dec;34(12):1369-76
pubmed: 26379164
Semin Pediatr Infect Dis. 2003 Jul;14(3):220-32
pubmed: 12913835
BMJ Open. 2016 Dec 20;6(12):e011317
pubmed: 27998896
BMC Public Health. 2019 Nov 11;19(1):1506
pubmed: 31711464
BMJ. 2000 Dec 9;321(7274):1435-8
pubmed: 11110734
Lancet. 2003 Jun 28;361(9376):2183-8
pubmed: 12842371
BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
BMJ. 1995 Aug 19;311(7003):481-5
pubmed: 7647643
Lancet Glob Health. 2014 Aug;2(8):e478-87
pubmed: 25103521
Trop Med Int Health. 2017 Jan;22(1):12-20
pubmed: 27717100
Lancet Infect Dis. 2020 Oct;20(10):e274-e283
pubmed: 32645296
Front Public Health. 2018 Feb 02;6:13
pubmed: 29456992
Pediatr Infect Dis J. 2016 Nov;35(11):1232-1241
pubmed: 27753769
Vaccine. 2017 Jan 3;35(1):33-39
pubmed: 27890397
Vaccine. 2014 Jan 23;32(5):598-605
pubmed: 24325827